Becton Dickinson & Co. – FDA 483, Jul 23, 2021
Becton Dickinson & Co. in Sparks, MD, a medical device manufacturer, received a Form FDA 483 for inadequate documentation of design risk analysis results. The firm failed to properly document new risks and mitigation actions identified during Corrective and Preventive Action (CAPA) investigations for recalled products. This deficiency was observed in relation to BD Phoenix™ AST Indicators and BD MAX™ Enteric Bacterial Panel assay kits, indicating a lack of control over identified risks and failure modes.
ID · d7a5ae09-1b7a-4536-8200-45a6534aedf3
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.